Aldomet

(Methyldopa)

ApprovedSmall molecule

Neurocrine Biosciences

Aldomet is one of 96 small molecule programs targeting Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

PreeclampsiaActive, not recruiting

Type 1 DiabetesActive, not recruiting

Chronic Fatigue SyndromeActive, not recruiting

HypertensionApproved

Active, not recruiting

PreeclampsiaPhase 2

Active, not recruiting

Type 1 DiabetesPreclinical

Active, not recruiting

Chronic Fatigue SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Aldomet

Neurocrine Biosciences

Approved

3 2

Edarbi

Takeda

Preclinical

10 3

Benicar

Novartis

Preclinical

7 4

Zebeta

Teva

Preclinical

6 5

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 6

Winrevair

Alphagan

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 9

Avastin

BBio-Thera Solutions

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension3 trials

Treatment Targets for Chronic Hypertension in Pregnancy

Withdrawn·WWeill Medical College of Cornell University·Phase 1/2·NCT00194974

Management of Hypertension in the Early Postpartum: a Randomized Controlled Trial

Completed·FFederal University of Paraíba·Phase 4·NCT04835233·180 enrolled

Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy

Completed·GGynuity Health Projects·Phase 4·NCT01912677·894 enrolled

Type 1 Diabetes2 trials

Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes

Withdrawn·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03396484

Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

Completed·UUniversity of Colorado, Denver·N/A·NCT01883804·30 enrolled

Preeclampsia2 trials

Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia

Completed·IIsfahan University of Medical Sciences·Phase 2·NCT01674127·50 enrolled

Community Level Interventions for Pre-eclampsia

Completed·UUniversity of British Columbia·N/A·NCT01911494·87,500 enrolled

Chronic Fatigue Syndrome1 trial

Autonomic Nervous System and Chronic Fatigue Syndrome

Completed·VVanderbilt University·Phase 1·NCT00580619·170 enrolled

Pregnancy1 trial

Early Vascular Adjustments During Hypertensive Pregnancy

Unknown status·MMaastricht University Medical Center·Phase 4·NCT02531490·368 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

ALDOMET

NDA NDA018389

Jan 1, 1982

ALDOMET

NDA NDA013400

Jun 29, 1984

METHYLDOPA

NDA NDA018934

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Methyldopa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methyldopa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methyldopa. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018934). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Neurocrine Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Neurocrine Biosciences

Aldomet

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertension3 trials

Type 1 Diabetes2 trials

Preeclampsia2 trials

Chronic Fatigue Syndrome1 trial

Pregnancy1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News